Some material for DD in biomed world. 3D hype is on fire, 3D is here to stay, genomics is a future already here.
ONVO- 3D biotissue printing, real functional liver tissue printing. Could save big pharma millions. Buyout is a possibility. A lot of hype around. Not ready for long term investment till they start making some real money. Short term/day trading on chart/tech indicators is an option. I was trading this one, now I am sitting out. Will go back in on any major fundamental change or positive cash flow.
FLDM- Human and plant genomics. No FDA, no hype, as all bio juniors possible buyout. Already making money. Last earning report was very good, probably will make a repeat in January. I am in.
EVGN- Plant genomics. No FDA, no hype. Recent IPO, has partnership with all major agricultural companies. I
Came sooner than expected! Now will some real buying start. Quite possible that some less informed shorts will stage a few attacks. That will be a buying opportunity. Still waiting for Ofirmev on this side of the border. GTLA
We go 10 before New Year. Some heavy silent buying going around. I hope no buyout offer at this point....
Someone is betting on a big surprise in January. Today bot over 2000 call contracts for January, strike price 95$, and over 2000 call contracts for January, strike price 105$. What could be? Earnings surprise, buyout offer, or else?...
What happened with Adam, TD, Cramer and other shorts? TD went under the rock, Adam will never admit he was wrong. Oh, sure, shorts will try again. Good luck. Any short selling will be a buying opportunity. Former resistance ( 7$ ) is now new support. Ofirmev sales will go up, and up, and up by itself. It is auto pilot, docs do not need reps to tell them how to use acetaminophen. They just say bring it in hospital. Add Canadian start and big pharma buyout consideration
Blue sky from here. Any short selling will be met with intense buying. I am loading up. So glad they got rid of Baxter. If they are looking for new acquisition I would suggest to look at RGDO. RGDO has in hospital product, clinical trial phase 3, proven safety and efficacy.
Shorts will try for sure another spin. Let me see: one-Ofirmev is "expensive", two-FDA issued "black box", three-they need more money.
- Ofirmev is, will be number one IV non-narcotic pain med in US and Canada
- they only scratched non-surgical, ER, ICU and pediatric market
- Ofirmev is SAVING money ( shorter stay, less side effects, better pain control )
- FDA black box is targeting ORAL acetaminophen
- CADX will be profitable in 2014, Ofimev price will go up, no generics
- no second offering unless new acquisition
- once on formulary there is no need for expensive sale force, unless new acquisition
- at this point legit buyout target
If true 7-8$ tomorrow and up from now on. Now, buyout offer could be in the cards...
Numbers speak loud for themselves. Guidance crash MW theory. Expect another spin and shorts attack at open. Not that will make a big difference but it would help to remove all sell stop orders and place sell limit orders at 20. How about stop buy orders at 16?....